FKBPL: a marker of good prognosis in breast cancer-Reference-Cited by-同舟云学术

FKBPL: a marker of good prognosis in breast cancer

Published:2015-04-03 Issue:14 Volume:6 Page:12209-12223
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Nelson Laura¹,McKeen Hayley D.¹,Marshall Andrea²,Mulrane Laoighse³,Starczynski Jane⁴,Storr Sarah J.⁵,Lanigan Fiona³,Byrne Christopher⁶,Arthur Ken⁷,Hegarty Shauna⁸,Ali Ahlam Abdunnabi¹,Furlong Fiona¹,McCarthy Helen O.¹,Ellis Ian O.⁵,Green Andrew R.⁵,Rakha Emad⁵,Young Leonie⁶,Kunkler Ian⁹,Thomas Jeremy⁹,Jack Wilma⁹,Cameron David⁹,Jirström Karin¹⁰,Yakkundi Anita¹,McClements Lana¹,Martin Stewart G.⁵,Gallagher William M.³,Dunn Janet²,Bartlett John⁴¹¹,O’Connor Darran³,Robson Tracy¹

Affiliation:

1. School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom

2. Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom

3. Conway Institute, University College Dublin, Dublin, Ireland

4. Ontario Institute for Cancer Research, Toronto, Canada

5. Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom

6. Royal College of Surgeons Ireland, Dublin, Ireland

7. Northern Ireland Molecular Pathology Laboratory, CCRCB, Queens University Belfast, Belfast, United Kingdom

8. Department of Pathology, Royal Group of Hospitals, Grosvenor Road, Belfast, United Kingdom

9. Edinburgh Breast Unit, The University of Edinburgh, Edinburgh, United Kingdom

10. Department of Clinical Sciences, Lund University, Sweden

11. Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, United Kingdom

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression and role of FKBPL in lung adenocarcinoma;Journal of Cancer;2024

2. Loss of Expression of Antiangiogenic Protein FKBPL in Endometrioid Endometrial Carcinoma: Implications for Clinical Practice;Medicina;2022-09-22

3. A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours;British Journal of Cancer;2022-05-14

4. FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function;Frontiers in Endocrinology;2021-06-02

5. The immunophilin protein FKBPL and its peptide derivatives are novel regulators of vascular integrity and inflammation via NF-κB signaling;2021-02-25